To compare the efficacy and safety of low dose tofacitinib versus oral corticosteroid (dexamethasone) mini pulse along with topical PUVAsol in stabilization and repigmentation of cutaneous lesions in rapidly progressive vitiligo. An open label active controlled randomized study.

An open-label two-arm randomized prospective non inferior active controlled study with intention to treat to compare the efficacy and safety of low dose tofacitinib versus oral corticosteroid (dexamethasone) mini pulse along with topical PUVAsol in the stabilization and repigmentation of rapidly progressive vitiligo with Body surface area less than 5 percent.Vitiligo patient with active disease VIDA 4 and having vitiligo for more than 6 months adult of age group 18-60 years old of any sex, presenting to the Dermatology OPD and  providing written informed consent. Patients unwilling to give written informed consent to participate in the study,with other major dermatological ailments (Immunobullous disease, SLE, Connective tissue diseases, Autoimmune diseases,Vasculitis),with underlying hepatic, renal diseases, coronary artery disease (CAD) or any major contraindications to the use of tofacitinib,Pregnant, lactating female will be excluded.Participants will be randomised using computer generated random number.Primary objectives are to evaluate the number of patients achieving the arrest of progression of the disease ,decrease of VIDA score by 1 point in low dose tofacitinib (Group A) and oral corticosteroid (dexamethasone) mini pulse (Group B) at 16 weeks.To evaluate number of patients achieving more than 50 percent of repigmentation in each group at 16 weeks.Secondary objectives are to evaluate the percentage of patients maintaining arrest of the disease in each group at 24 weeks.To compare the patients achieving arrest of progression and repigmentation between the groups A and B at 16 and 24 weeks.To evaluate change in mean VASI and mean Physician global assessment scores from baseline to end of 16 weeks and end of 24 weeks within and between groups A and B.To analyse patient global assessment using patient satisfaction score and Patient reported outcome measures (PROM) VitiQoL at 16 and 24 weeks within and between group A and group B.